Evidence map›Paper›PMID 39202414›Full record

ArticleGenes2024

Gene Variants in Components of the microRNA Processing Pathway in Chronic Myeloid Leukemia.

Guillermina Chavaro-Francisco, Araceli Hernández-Zavala, Camila E Bravo-Cidro, Sandybel Rios-Rodriguez, Mabel Muciño-Sánchez, Marisol López-López, Xóchitl H Castro-Martínez, Irma Olarte-Carrillo, Anel Garcia-Laguna, Gilberto Barranco-Lampón and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Guillermina Chavaro-FranciscoSection of Research and Postgraduate Studies, Superior School of Medicine, National Institute Polytechique, Mexico City 11340, Mexico.
Araceli Hernández-ZavalaSection of Research and Postgraduate Studies, Superior School of Medicine, National Institute Polytechique, Mexico City 11340, Mexico.ORCID 0000-0002-0848-2927
Camila E Bravo-CidroOncogenomics Consortium Laboratory, Clinic Research Department, National Institute of Genomic Medicine, Mexico City 14610, Mexico.
Sandybel Rios-RodriguezOncogenomics Consortium Laboratory, Clinic Research Department, National Institute of Genomic Medicine, Mexico City 14610, Mexico.
Mabel Muciño-SánchezOncogenomics Consortium Laboratory, Clinic Research Department, National Institute of Genomic Medicine, Mexico City 14610, Mexico.
Marisol López-LópezDepartment of Biological Systems, Metropolitan Autonomous University, Campus Xochimilco, Mexico City 04960, Mexico.ORCID 0000-0002-3954-8052
Xóchitl H Castro-MartínezGenomics of Psychiatric and Neurogenerative Diseases Laboratory, National Institute of Genomic Medicine, Mexico City 14610, Mexico.ORCID 0000-0002-9239-6481
Irma Olarte-CarrilloMolecular Biology Laboratory, Service of Hematology, Hospital General de Mexico, "Dr. Eduardo Liceaga", Mexico City 06720, Mexico.
Anel Garcia-LagunaMolecular Biology Laboratory, Service of Hematology, Hospital General de Mexico, "Dr. Eduardo Liceaga", Mexico City 06720, Mexico.
Gilberto Barranco-LampónMolecular Biology Laboratory, Service of Hematology, Hospital General de Mexico, "Dr. Eduardo Liceaga", Mexico City 06720, Mexico.ORCID 0000-0002-2988-7544
Adrián De la Cruz-RosasMolecular Biology Laboratory, Service of Hematology, Hospital General de Mexico, "Dr. Eduardo Liceaga", Mexico City 06720, Mexico.
Adolfo Martínez-TovarMolecular Biology Laboratory, Service of Hematology, Hospital General de Mexico, "Dr. Eduardo Liceaga", Mexico City 06720, Mexico.ORCID 0000-0002-5713-3731
Emilio J CórdovaOncogenomics Consortium Laboratory, Clinic Research Department, National Institute of Genomic Medicine, Mexico City 14610, Mexico.

Funding

Consejo Nacional de Humanidades, Ciencia y Tecnología FOSISS A3-S-45155
6 · The paper itself

Abstract

Current therapy in chronic myeloid leukemia (CML) has improved patient life expectancy close to that of healthy individuals. However, molecular alterations other than BCR::ABL1 fusion gene in CML are barely known. MicroRNAs are important regulators of gene expression, and variants in some of the components of microRNA biosynthesis pathways have been associated with genetic susceptibility to different types of cancer. Thus, the aim of this study was to evaluate the association of variants located in genes involved in the biogenesis of microRNAs with susceptibility to CML. Fifteen variants in eight genes involved in the biogenesis of miRNAs were genotyped in 296 individuals with CML and 485 healthy participants using TaqMan probes. The association of gene variants with CML and clinical variables was evaluated by a Chi-square test, and odds ratios and 95% confidence intervals were estimated by logistic regression. The variant rs13078 in

Indexed as

DEAD-box RNA HelicasesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMicroRNAsPolymorphism, Single NucleotideRibonuclease IIIAdultAgedCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPrognosisDEAD-box RNA HelicasesDICER1 protein, humanMicroRNAsRibonuclease IIIchronic myeloid leukemiagene variantsHasford scoremicroRNAs biogenesis

Identifiers

PMID39202414
PMCPMC11353722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.